The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension

S. Rich, B. H. Brundage, P. S. Levy

Research output: Contribution to journalArticlepeer-review

87 Scopus citations


The short- and long-term hemodynamic effects of vasodilators in patients with primary pulmonary hypertension have been studied, but whether they affect survival is unknown. We measured the short-term response to nifedipine and hydralazine in 23 patients with primary pulmonary hypertension and followed their clinical course over 2 years. A favorable drug response, defined as a fall in the pulmonary vascular resistance of 20% or greater, occurred in 18 patients (78%). Half of the patients who exhibited a favorable short-term response were treated with long-term vasodilator therapy. Their clinical course was compared with that of responders who were not treated and with that of the nonresponders. Of the responders who were treated, 2 improved, 4 had no change, and 3 died; of the responders who were not treated, 1 improved, 3 had no change, and 5 died. Using stepwise Cox regression, we evaluated age, sex, functional class on entry, pulmonary arterial pressure, pulmonary vascular resistance, and short-term drug response as predictors of survival and found only functional class and a favorable short-term drug response to be significant predictors (p < .01); however, there was no difference in survival between the responders who were treated and those who were not. We conclude that the ability to respond to short-term nifedipine or hydralazine therapy predicts longer survival for patients with primary pulmonary hypertension, but placing patients with a favorable short-term response on long-term vasodilator therapy does not affect the overall outcome.

Original languageEnglish (US)
Pages (from-to)1191-1196
Number of pages6
Issue number6
StatePublished - 1985

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)


Dive into the research topics of 'The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension'. Together they form a unique fingerprint.

Cite this